Our findings suggest that methionine cycle inhibition via limiting methionine intake or targeting MAT2A reduces the tumorigenicity of GBM tumor-initiating cells, highlighting the great therapeutic potential of drugs against methionine cycle activity for the eradication of GSC-like cells in patients with GBM. The gene discussed is MAT2A; the disease is glioblastoma.